Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amneal Pharmaceuticals reports strong Q4 earnings and outlines growth strategies

Amneal Pharmaceuticals delivered strong Q4 2022 results with revenue of $610 million and adjusted EBITDA of $154 million, expecting stable performance in 2023 with total revenue of $2.25-2.35 billion.
The company's strategic focus on complex, high-growth products, international expansion, and new product launches positions it for growth opportunities despite challenges in generic growth rates and competitive pressures.
With a robust biosimilars growth plan, unique pricing strategies, and market expansion initiatives, Amneal Pharmaceuticals aims to capture market share, drive revenue growth, and sustain its performance in the pharmaceutical industry.
Despite facing challenges such as potential competition and manufacturing delays, Amneal Pharmaceuticals remains optimistic about its growth prospects, emphasizing long-term strategies for revenue expansion and market positioning.

Amneal Pharmaceuticals reports strong Q1 results and eyes strategic growth

Amneal Pharmaceuticals' Q1 2023 performance reflects strategic growth initiatives across all segments, positioning the company for future success.
While challenges like debt reduction and refinancing exist, the company's strengths in product diversification and market adoption offer growth potential.
Opportunities in Injectables, Biosimilars, and capital allocation strategies provide avenues for revenue growth and operational excellence.

Amneal Pharmaceuticals reports strong Q2 earnings, eyes sustainable growth

Amneal Pharmaceuticals is on track for sustainable growth and EBITDA acceleration.
The company is well-positioned to capitalize on the growth potential in biosimilars and complex generics.
With a focus on organic growth and new product launches, Amneal aims to drive revenue and expand market share.

Amneal Pharmaceuticals excels in Q3, eyes international expansion and specialty growth

Amneal Pharmaceuticals reported strong financials, raised guidance, and highlighted growth in key segments. The company's strategic focus on operational efficiency, supply chain expansion, and international growth positions it for sustained success. Challenges include managing expenses and liabilities, but opportunities in new markets and product segments offer avenues for growth.

Amneal Pharmaceuticals posts record revenue in Q4 2023, eyes biosimilar growth

Amneal Pharmaceuticals reported robust financials for Q4 2023 and full-year 2023, with record revenue and EBITDA figures. The company's strategic focus on biosimilars, portfolio expansion, and growth initiatives underpin its optimistic outlook for 2024. Despite industry challenges, Amneal remains committed to innovation, affordability, and addressing pricing issues.

Amneal Pharmaceuticals reports record Q1 revenues and eyes biosimilar growth

Amneal Pharmaceuticals' Q1 performance reflects robust growth across all segments, underpinned by strong financial execution and a sustainable growth profile.
The company's strengths lie in its market position, diverse portfolio, commitment to quality, and strategic partnerships, positioning them for continued success.
While facing challenges related to product approvals and revenue uncertainties, Amneal is well-positioned to capitalize on opportunities in biosimilars, strategic partnerships, and market expansion.

Amneal Pharmaceuticals excels in Q2, eyes international expansion for growth

Amneal Pharmaceuticals delivered a strong performance in Q2 2024, with robust revenue growth and raised guidance, signaling confidence in future prospects.
The company's strategic strengths lie in international expansion, diversified revenue streams, and a focus on financial stability through debt reduction and investments.
Challenges include maintaining growth momentum, effective execution of expansion plans, and balancing debt reduction with growth investments.
Opportunities abound in new product approvals, market expansion, and innovation, positioning Amneal Pharmaceuticals for sustained growth and market leadership.

Amneal Pharmaceuticals reports robust Q3 results and eyes future growth

Amneal Pharmaceuticals' Q3 performance reflects strong revenue growth and strategic product initiatives in key therapeutic areas.
The company's focus on affordable medicines, biosimilars, and strategic investments underscores its commitment to future growth.
While facing challenges in market competition and operational optimization, Amneal is well-positioned to leverage growth opportunities.
With a solid financial performance and a focus on sustainable value creation, Amneal is poised for long-term success in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Shares of Amneal Pharmaceuticals AMRX, -0.57% jumped 33% in premarket trading after the generic drugmaker said Thursday that it has started selling EluRyng, the first generic version of Merck's MRK, -0.13% birth-control NuvaRing.

Amneal stock jumps on launch of first generic NuvaRing

AmerisourceBergen

Endo International

Johnson & Johnson

McKesson

Mallinckrodt PLC

Teva Pharmaceutical

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

Fed Reportedly Opens Criminal Investigation on Opioid Makers

Pharmaceutical companies are in trouble over their role in fueling the opioid crisis facing the U.S.

Pharma Companies Shares Tank As Feds Investigate Opioid Crisis

Federal prosecutors have opened a criminal investigation into whether pharmaceutical companies intentionally allowed opioid painkillers to flood communities, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Federal prosecutors open criminal probe of opioid makers, distributors: WSJ

Cardinal Health

Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources.

Shares of opioid makers and distributors drop on criminal probe

It’s been a rough 2019 for some biotechs. Amneal Pharmaceuticals Inc (NYSE: AMRX) is down 81% year-to-date, while Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is down 41%.

Teva Vs. Amneal: JPMorgan Sees Hope For One, Decline For The Other

Amneal Pharmaceuticals Inc. (AMRX) CEO Chirag Patel on Q3 2019 Results - Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of -69.23% and -4.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Lags Q3 Earnings and Revenue Estimates

Amneal Pharmaceuticals, Inc. (AMRX) CEO Chirag Patel on Q2 2019 Results - Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of -40.00% and -6.21%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Lag Estimates

Amneal Pharmaceuticals (NYSE: AMRX) reported second-quarter earnings of 9 cents per share, which missed the analyst consensus estimate of 14 cents by 35.71%.

Amneal Pharmaceuticals Reports Q2 Earnings Miss, Lowers Guidance

Assertio Therapeutics Inc

ASRT vs. AMRX: Which Stock Is the Better Value Option?

ASRT or AMRX: Which Is the Better Value Stock Right Now?

Mylan

Pharmaceutical stocks Teva Pharmaceutical, Mylan, Endo and Amneal Pharmaceuticals may have to pay $8.5 billion in litigation costs surrounding the opioid epidemic, an analyst said Monday.

These Pharmas Could Be On The Hook For Billions In The Opioid Epidemic

Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

Amneal (AMRX) Down on Guidance Update & Restructuring Plan

Micro Focus International PLC

MSC Industrial Direct

Company-specific bad news kept these stocks out of the rally.

Why Micro Focus International, MSC Industrial Direct, and Amneal Pharmaceuticals Slumped Today

Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.

Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today

Amneal Pharmaceuticals (NYSE: AMRX) has reduced EBITDA for 2019 to now be in the range of $425 million to $475 million.

Amneal Announces Restructuring Plan, Cuts Guidance

Lannett Company

The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.

Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May

Amneal Pharmaceuticals' (AMRX) CEO Rob Stewart on Q1 2019 Results - Earnings Call Transcript

Investors were none too pleased with Amneal's first-quarter performance. Here's why.

Why Amneal Pharmaceuticals Stock Is Cratering Today

Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Amneal Pharmaceuticals Stock (AMRX)